The platform that we had designed for our client helped them leapfrog their way through the mundane and time-consuming processes hindering the successful and timely completion of the FIH process. The committee was no longer burdened by collaboration and alignment problems. The researchers had access to new and sophisticated ways to extract meaningful insights from vast data sourced from the preclinical trials.
Moreover, the platform’s effectiveness lied in the combined effect of its simple, intuitive user interface and the advanced capabilities that it brought to the researcher’s arsenal. Some of the most noticeable results that the platform has had are detailed below.
Liked this transformation story?
Let's build yours now.
Starting with study types, researchers were now able to re-order and filter the study types in any order they deem fit. The concentration of the assays within specific study types could now be plotted against linear and logarithmic ranges. The platform also allowed researchers to apply free fractions to determine the level that works best.
Optimize Drug Risk-Benefit
The platform could calculate exposure to effectively determine the dose that strikes the right balance between drug efficacy and adverse effects. Its capabilities extended to calculating the exposure multiples across two studies and then comparing them with each other.
With so many filters, values, and findings to juggle around, there was a pressing need for a sufficiently versatile data viewing and slicing feature that researchers could make use of on the fly. Our platform allowed for different views to categorize across human, species, and non-species studies and boasts of tag and color coding to bestow researchers with the ability to define their filtering framework for convenience.
The platform also came with an auto-translation of nM to ng/ml, the ability to toggle between total and free-form values. This pinned tooltip feature provided information about points and ensures that IB documents are tagged to the corresponding assays.